These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 16313289)

  • 21. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study.
    Van der Bij AK; Kloosterboer N; Prins M; Boeser-Nunnink B; Geskus RB; Lange JM; Coutinho RA; Schuitemaker H
    J Infect Dis; 2005 Mar; 191(5):678-85. PubMed ID: 15688280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of GB virus C co-infection on response to generic HAART in African patients with HIV-1 clade C infection.
    Mosam A; Sathar MA; Dawood H; Cassol E; Esterhuizen TM; Coovadia HM
    AIDS; 2007 Jun; 21(10):1377-9. PubMed ID: 17545721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of GB virus C viraemia on clinical outcome in HIV-1-infected patients: a 20-year follow-up study.
    Ernst D; Greer M; Akmatova R; Pischke S; Wedemeyer H; Heiken H; Tillmann HL; Schmidt RE; Stoll M
    HIV Med; 2014 Apr; 15(4):245-50. PubMed ID: 24118889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GB virus C coinfection and vertical transmission in HIV-infected mothers before the introduction of antiretroviral prophylaxis.
    Barqasho B; Navér L; Bohlin AB; Lindgren S; Hultgren C; Birk M
    HIV Med; 2004 Nov; 5(6):427-30. PubMed ID: 15544695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.
    Anderson AM; Kosinski AS; Bartlett JA
    Antivir Ther; 2007; 12(7):1041-8. PubMed ID: 18018762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent GB virus C infection and survival in HIV-infected men.
    Williams CF; Klinzman D; Yamashita TE; Xiang J; Polgreen PM; Rinaldo C; Liu C; Phair J; Margolick JB; Zdunek D; Hess G; Stapleton JT
    N Engl J Med; 2004 Mar; 350(10):981-90. PubMed ID: 14999110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mother-to-child transmission of GB virus C in a cohort of women coinfected with GB virus C and HIV in Bangkok, Thailand.
    Bhanich Supapol W; Remis RS; Raboud J; Millson M; Tappero J; Kaul R; Kulkarni P; McConnell MS; Mock PA; McNicholl JM; Vanprapar N; Asavapiriyanont S; Shaffer N; Butera S
    J Infect Dis; 2009 Jul; 200(2):227-35. PubMed ID: 19508162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No observed effect of GB virus C coinfection on disease progression in a cohort of African woman infected with HIV-1 or HIV-2.
    Kaye S; Howard M; Alabi A; Hansmann A; Whittle H; Schim van der Loeff M
    Clin Infect Dis; 2005 Mar; 40(6):876-8. PubMed ID: 15736023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of circulating natural type 1 interferon-producing cells in HIV/GBV-C and HIV/HCV coinfected patients: a preliminary study.
    Haji Molla Hoseini M; Pourfathollah AA; Mohraz M; Soheili Z; Amini S; Aghaiepour M; Samiee S; Nikoogoftar M; Meshkani R
    Arch Med Res; 2007 Nov; 38(8):868-75. PubMed ID: 17923269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.
    Brumme ZL; Chan KJ; Dong WW; Mo T; Wynhoven B; Hogg RS; Montaner JS; O'Shaughnessy MV; Harrigan PR
    AIDS; 2002 Sep; 16(14):1929-33. PubMed ID: 12351953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.